Literature DB >> 27521450

Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.

Carter M Suryadevara1,2,3, Katherine A Riccione1,2,4, John H Sampson5,2,3,4.   

Abstract

Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma. Clin Cancer Res; 22(21); 5164-6. ©2016 AACRSee related article by Yoo et al., p. 5265. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27521450      PMCID： PMC5093093          DOI： 10.1158/1078-0432.CCR-16-1666

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  9 in total

1.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Authors:  John H Sampson; Amy B Heimberger; Gary E Archer; Kenneth D Aldape; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert J Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

Review 2.  The proteasome: a suitable antineoplastic target.

Authors:  Julian Adams
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

3.  Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Authors:  Ji Young Yoo; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Hongsheng Dai; Tejaswini Nallanagulagari; Jeffrey Wojton; Brian S Hurwitz; Theresa Relation; Tae Jin Lee; Michael T Lotze; Jun-Ge Yu; Jianying Zhang; Carlo M Croce; Jianhua Yu; Michael A Caligiuri; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2016-07-07       Impact factor: 12.531

Review 4.  Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.

Authors:  Christopher A Alvarez-Breckenridge; Bryan D Choi; Carter M Suryadevara; E Antonio Chiocca
Journal:  Curr Opin Virol       Date:  2015-04-04       Impact factor: 7.090

Review 5.  Molecular mechanisms of necroptosis: an ordered cellular explosion.

Authors:  Peter Vandenabeele; Lorenzo Galluzzi; Tom Vanden Berghe; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2010-09-08       Impact factor: 94.444

6.  Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Authors:  Ji Young Yoo; Brian S Hurwitz; Chelsea Bolyard; Jun-Ge Yu; Jianying Zhang; Karuppaiyah Selvendiran; Kellie S Rath; Shun He; Zachary Bailey; David Eaves; Timothy P Cripe; Deborah S Parris; Michael A Caligiuri; Jianhua Yu; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2014-05-09       Impact factor: 12.531

7.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Authors:  Peter E Fecci; Duane A Mitchell; John F Whitesides; Weihua Xie; Allan H Friedman; Gary E Archer; James E Herndon; Darell D Bigner; Glenn Dranoff; John H Sampson
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

8.  NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.

Authors:  Christopher A Alvarez-Breckenridge; Jianhua Yu; Richard Price; Jeffrey Wojton; Jason Pradarelli; Hsiaoyin Mao; Min Wei; Yan Wang; Shun He; Jayson Hardcastle; Soledad A Fernandez; Balveen Kaur; Sean E Lawler; Eric Vivier; Ofer Mandelboim; Alessandro Moretta; Michael A Caligiuri; E Antonio Chiocca
Journal:  Nat Med       Date:  2012-11-25       Impact factor: 53.440

Review 9.  Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.

Authors:  Jianfang Ning; Hiroaki Wakimoto
Journal:  Front Microbiol       Date:  2014-06-20       Impact factor: 5.640
  9 in total
  4 in total

Review 1.  NK cells in the brain: implications for brain tumor development and therapy.

Authors:  Agisilaos Balatsoukas; Filippo Rossignoli; Khalid Shah
Journal:  Trends Mol Med       Date:  2022-01-22       Impact factor: 11.951

2.  Alternol triggers immunogenic cell death via reactive oxygen species generation.

Authors:  Changlin Li; Ying Zhang; Siyuan Yan; Guoan Zhang; Wei Wei; Zhi Qi; Benyi Li
Journal:  Oncoimmunology       Date:  2021-07-21       Impact factor: 8.110

Review 3.  The Role of NK Cells and Innate Lymphoid Cells in Brain Cancer.

Authors:  Alexander James Sedgwick; Nazanin Ghazanfari; Patrick Constantinescu; Theo Mantamadiotis; Alexander David Barrow
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

Review 4.  Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell.

Authors:  Chaopin Yang; Yue Li; Yaozhang Yang; Zhiyi Chen
Journal:  J Immunol Res       Date:  2020-01-21       Impact factor: 4.818
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.